Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Autolus Therapeutics (Nasdaq: AUTL) granted inducement equity awards under its 2025 Inducement Plan on April 14, 2026.

Rhea-AI Summary

Autolus Therapeutics (Nasdaq: AUTL) granted inducement equity awards under its 2025 Inducement Plan on April 14, 2026. The Compensation Committee awarded options for 68,500 ADS and 57,765 RSUs to 15 employees, with options priced at $1.47 and ten-year terms.

Options vest over four years (25% after one year, then monthly over three years); RSUs vest in four equal annual installments. Awards are conditioned on continued service and were granted as inducements under Nasdaq Listing Rule 5635(c)(4).

Argus Apr 22 session

+3.23% close to close Open Argus

Details

News Market Reaction – AUTL

In the Apr 22 session, AUTL gained 3.23%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details routine inducement equity awards—68,500 stock options and 57,765 RSUs—to 1...

Analysis

This announcement details routine inducement equity awards—68,500 stock options and 57,765 RSUs—to 15 new employees under Nasdaq Listing Rule 5635(c)(4), with a $1.47 exercise price and four-year vesting. In context, Autolus recently filed a $150,000,000 Form S-3 shelf and reported 2025 revenue growth and guidance. Investors may monitor how ongoing hiring, equity incentives and any future shelf usage interact with the company’s cash runway and commercial ramp.

Key Figures

Current price: $1.58 Stock options granted: 68,500 ADS RSUs granted: 57,765 RSUs +5 more

Current price

$1.58

As of latest pre-news market context

Stock options granted

68,500 ADS

Inducement awards under 2025 Inducement Plan to new employees

RSUs granted

57,765 RSUs

Inducement awards, each RSU equal to one ordinary share

Employees receiving grants

15 employees

New hires receiving inducement equity awards

Option exercise price

$1.47 per share

Equal to closing price on April 13, 2026

Option term

10 years

Stock option awards under inducement plan

Shelf registration size

$150,000,000

Form S-3 shelf filed April 10, 2026

Ordinary shares issued

266,143,286 shares

Outstanding as of December 31, 2025 per S-3 prospectus

Historical Context

5 past events · Latest: Apr 07

5 events

1. Apr 07

   Conference participation

   24h Move

   -2.2%

   Investor conference participation and webcasts announced for April 2026.

2. Mar 27

   Earnings and outlook

   24h Move

   -6.2%

   Reported 2025 revenue and AUCATZYL guidance with outlook to positive gross margin.

3. Mar 16

   Earnings date set

   24h Move

   +0.0%

   Announced timing and access details for Q4 and full-year 2025 results call.

4. Feb 24

   Conference participation

   24h Move

   +5.2%

   Outlined March 2026 investor events featuring CEO presentations and meetings.

5. Feb 04

   Inducement grants

   24h Move

   +0.0%

   Announced prior inducement stock option awards under Nasdaq Listing Rule 5635(c)(4).

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

american depositary shares, restricted stock units, nasdaq listing rule 5635(c)(4), exercise price, +1 more

5 terms

american depositary shares financial

"granted stock option awards to purchase an aggregate of 68,500 American Depositary Shares"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

restricted stock units financial

"and 57,765 restricted stock units (RSUs), each representing an equal number"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"as an inducement material to the individual becoming an employee of Autolus in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

exercise price financial

"The stock option awards have an exercise price of $1.47 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"Each stock option award has a ten-year term and vests over four years, with 25% of the original number of shares vesting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LONDON and GAITHERSBURG, Md., April 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Compensation Committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 68,500 American Depositary Shares and 57,765 restricted stock units (RSUs), each representing an equal number of ordinary shares, to 15 employees pursuant to the Company’s 2025 Inducement Plan. The stock options and RSUs were granted as an inducement material to the individual becoming an employee of Autolus in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock option awards and RSUs have a grant date of April 14, 2026. The stock option awards have an exercise price of $1.47 per share, which is equal to the closing price of Autolus’ common stock on April 13, 2026. Each stock option award has a ten-year term and vests over four years, with 25% of the original number of shares vesting on the one-year anniversary of the hire date of the employee and the remainder vesting in 36 equal monthly installments thereafter. Each RSU vests in four equal annual installments. The options and RSUs are subject to the employee's continued service with Autolus through the applicable vesting dates.

About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL^®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.

Contact:  

Amanda Cray 
Executive Director, Investor Relations & External Communications
+1 617-967-0207 
a.cray@autolus.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Autolus (AUTL) grant on April 14, 2026?

Autolus granted stock options for 68,500 ADS and 57,765 RSUs to 15 employees. According to the company, awards were issued under the 2025 Inducement Plan as inducements material to employment.

What is the exercise price and term of the Autolus (AUTL) stock options?

The exercise price is $1.47 per share and each option has a ten-year term. According to the company, $1.47 equals the closing price on April 13, 2026.

How do Autolus (AUTL) stock options and RSUs vest for new hires?

Options vest over four years: 25% after one year, then monthly over 36 months; RSUs vest in four equal annual installments. According to the company, vesting requires continued service through applicable dates.

Why were the Autolus (AUTL) awards granted under Nasdaq Rule 5635(c)(4)?

The awards were granted as inducement material to employees joining Autolus, which fits Nasdaq Listing Rule 5635(c)(4). According to the company, this authorizes awards tied to new hires under the inducement plan.

How many employees received inducement awards from Autolus (AUTL)?

Fifteen employees received the inducement awards granted on April 14, 2026. According to the company, the aggregate awards total 68,500 ADS options and 57,765 RSUs across those hires.

Do Autolus (AUTL) awards require continued employment to vest?

Yes, both the options and RSUs are subject to the employee's continued service through each vesting date. According to the company, failure to remain employed may forfeit unvested awards.